FSLLRY-NH2 TFA

FSLLRY-NH2 blocks the ability of trypsin to activate PAR(2) either in PAR(2)-expressing Kirsten virus-transformed kidney (KNRK) cell lines or in a rat aorta ring preparation. The mechanism of this activity does not involve a simple inhibition of trypsin proteolytic activity, but possibly by interacting with a tethered ligand receptor-docking site.^{<a class="sref"href="#s_ref">[1]</a>}

KNRK cells are incubated with 10 nM trypsin  at 37°C for 10 to 60 min in the presence or absence of 200 μM FSLLRY-NH2. The absorbance of the released resorufin, reflecting proteolytic activity, is measured using a Beckman DU 640B Spectrophotometer at 574 nm for assay of proteolytic activity of trypsin.

Treatment with FSLLRY-NH2 significantly improves neurological outcome and reduces the number of degenerating hippocampal neurons after ACA (asphyxial CA).^{<a class="sref"href="#s_ref">[2]</a>}